|Awarded On||August 21, 2019|
|Title||Structure-based Drug Design of Inhibitors for a Breast Cancer Signature Kinase|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Elizabeth J Goldsmith|
*Pending contract negotiation
Structure-based Drug Design of Inhibitors for a Breast Cancer Signature Kinase Clinical identification of breast cancer subtypes allows for personalized treatment resulting in better outcomes. One subtype, basal-type breast cancer, is highly heterogeneous and associated with poor prognosis. Although it is not the most common form of breast cancer, its poor prognosis along with the lack of subtype specific treatments demand an increased focus on development of new therapies directed specifically at basal-type disease. Very recent studies implicate the protein kinase WNK1 as one of a handful of signature genes of basal-type breast cancer. Protein kinases are well-established drug targets i...